Jazz Pharmaceuticals vs PTC Therapeutics
JAZZ and PTCT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JAZZ and PTCT compare
Jazz Pharmaceuticals is the larger company, worth 2.8 times as much as PTC Therapeutics ($14.0B against $5.0B).
Jazz Pharmaceuticals grew revenue faster over the last twelve months (12.6% versus −35.1% for PTC Therapeutics).
Jazz Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 20.4% compared with −9.2% at PTC Therapeutics.
Jazz Pharmaceuticals scores higher on the StockData Score (11 against 5 for PTC Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JAZZ | PTCT |
|---|---|---|
| Size and price | ||
| Market cap | $14.0B | $5.0B |
| Share price | $215.98 | $59.97 |
| Change, 1 year | 59.1% | −11.0% |
| Change, 5 years | 59.9% | 45.2% |
| Beta (5Y) | 0.55 | 1.12 |
| Employees | 2,890 | 991 |
| StockData Score | ||
| Total score | 11 (better) | 5 |
| Valuation score | 4 (better) | 1 |
| Growth score | 1 | 1 |
| Performance score | 4 (better) | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 14.8× | – |
| P/S | 3.0× (better) | 4.3× |
| P/B | 2.9× | – |
| EV/EBITDA | 18.0× | 16.4× (better) |
| P/FCF | 8.8× (better) | 2421× |
| FCF yield | 11.4% (better) | 0.04% |
| Fair value | $254.92 | $46.85 |
| Margin of safety | 15.3% (better) | −28.0% |
| Growth | ||
| Revenue growth (TTM) | 12.6% (better) | −35.1% |
| Revenue growth, 5Y average | 12.5% | 35.4% (better) |
| Net income growth (TTM) | – | −114% |
| EPS growth (TTM) | – | −114% |
| Profitability | ||
| Operating margin | 19.5% (better) | 12.8% |
| Net margin | 20.4% (better) | −9.2% |
| FCF margin | 34.6% (better) | 0.18% |
| Return on equity | 22.1% | – |
| Return on invested capital | 12.1% | – |
| Financial health | ||
| Debt / equity | 0.91 | – |
| Net debt / EBITDA | 2.40 (better) | −7.63 |
| Current ratio | 1.78 | 3.27 (better) |
| Altman Z-score | 2.35 (better) | 0.77 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 99.2% | 120% |
| Held by insiders | 3.4% | 3.0% |
| Insider net buying, 12 months | −$68.0M | −$55.5M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 8.7% | 11.3% |
Go deeper
- JAZZ stock overview
- JAZZ income statement
- JAZZ valuation and score
- PTCT stock overview
- PTCT income statement
- PTCT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.